The most potent among the newer drugs are semaglutide and tirzepatide, both of which can lead to weight loss of about 20 per cent. Semaglutide, developed by Danish pharmaceutical company Novo Nordisk, is sold as Ozempic for the treatment of diabetes and at a higher dosage as Wegovy for obesity. US rival Eli Lilly markets tirzepatide as Mounjaro for diabetes and Zepbound for weight loss.
Early research, however, suggests that these glucagon-like peptide 1 (GLP-1) drugs may be able to do much more, such as treating dementia, addictions and mental conditions.
In March, Wegovy was approved by the US Food and Drug Administration for use to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are either obese or overweight.
In the same month, Novo Nordisk announced the early termination of its clinical trial for Ozempic - conducted in 28 countries with more than 3,500 participants - because of the very good early outcomes. It said the trial showed a significant 24 per cent reduction in the progression of chronic kidney disease and in cardiovascular and kidney-related deaths for people treated with 1mg of semaglutide compared with those receiving a placebo.
Such a big reduction in the progression of the disease could have a significant impact on the number of people getting kidney failure and requiring a transplant or lifelong dialysis.
“I can now tell my patients it will protect your kidneys,” said Dr Tham Kwang Wei, a senior endocrinologist at Woodlands Health.
هذه القصة مأخوذة من طبعة October 21, 2024 من The Straits Times.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة October 21, 2024 من The Straits Times.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
M2M to reunite for Singapore concert
It has been 22 years since they went away, but Norwegian pop duo M2M are back and coming to Singapore.
Industry sources say the author also wrote BTS memoir
Hybe's document on K-pop industry trends
Paddington Bear's 'high jinks' are back in third movie
LONDON - Paddington is back and he has lost none of his \"charm\" and \"high jinks\", according to English actor Hugh Bonneville, who again guides the trouble-prone bear through the third film in the hit series that saw its premiere on Nov 3.
Quincy Jones left indelible imprints on jazz, pop and hip-hop
LOS ANGELES - Quincy Jones, a major influence on American music in his work with artists ranging from Count Basie to Frank Sinatra and who then reshaped pop music by collaborating with Michael Jackson, died on Nov 3 at the age of 91.
Young Chinese pianist brings wealth of emotion
There are so many young Chinese pianists plying their art these days that it is easy to reduce them to Lang Lang, Yuja Wang, Li Yundi and the rest.
White faces, open mouths
Avant-garde Japanese dance butoh finds foothold in Singapore
Seeking sleep at Hoshinoya Tokyo
TOKYO In December 2023, I check into Hoshinoya Tokyo for a sleep retreat.
Explore the bustling Ginza and Marunouchi districts in Tokyo
Ginza, located near Tokyo Station, is one of the city's busiest high-end shopping districts.
Pastoral and scenic views at JW Marriott Jeju Resort & Spa
JEJU - The island bursts with juicy tangerines, and is where women well into their 80s free dive for seafood against a backdrop of dormant volcanoes and tea estates.
Connecting with the city's past at The Murray Hong Kong
Although brand-new hotels pop up all the time, restored heritage buildings-turned-hotels have an allure of their own.
